FDA gives the green light to the first gene therapy for deafness
4 hours ago
- #deafness-treatment
- #FDA-approval
- #gene-therapy
- The FDA has approved the first gene therapy aimed at restoring hearing for people born with certain genetic deafness, marking a historic milestone in treating hearing loss.
- The therapy is specifically for individuals with a rare defect in the OTOF gene, which prevents the production of the otoferlin protein needed for sound transmission from the ears to the brain.
- Treatment involves infusing a gene-carrying virus into the ear to deliver a healthy version of the OTOF gene, with many patients in trials showing significant hearing improvement within weeks.
- In clinical results, 80% of patients achieved at least some significant hearing restoration, and 42% attained normal hearing, including the ability to hear whispers.
- The approval is based on a study of 20 patients, with hearing gains lasting at least two years so far, described as 'incredible' and 'remarkable' by experts.
- While currently limited to a rare form of deafness affecting about 50 U.S. children annually, researchers hope similar gene therapies might eventually address more common types of hearing loss.
- The mother of a child who underwent the experimental treatment shared emotional stories of her son responding to sound for the first time, such as startling at loud laughter.
- Despite the optimism, some in the deaf community express concerns that such therapies could stigmatize deafness by framing it as a problem needing medical correction.